Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Abstract

The application of nanomedicines is increasing rapidly with the promise of targeted and efficient drug delivery. Nanomedicines address the shortcomings of conventional therapy, as evidenced by several preclinical and clinical investigations indicating sitespecific drug delivery, reduced side effects, and better treatment outcome. The development of suitable and biocompatible drug delivery vehicles is a prerequisite that has been successfully achieved by using simple and functionalized liposomes, nanoparticles, hydrogels, micelles, dendrimers, and mesoporous particles. A variety of drug delivery vehicles have been established for the targeted and controlled delivery of therapeutic agents in a wide range of chronic diseases, such as diabetes, cancer, atherosclerosis, myocardial ischemia, asthma, pulmonary tuberculosis, Parkinson's disease, and Alzheimer's disease. After successful outcomes in preclinical and clinical trials, many of these drugs have been marketed for human use, such as Abraxane®, Caelyx®, Mepact®, Myocet®, Emend®, and Rapamune®. Apart from drugs/compounds, novel therapeutic agents, such as peptides, nucleic acids (DNA and RNA), and genes have also shown potential to be used as nanomedicines for the treatment of several chronic ailments. However, a large number of extensive clinical trials are still needed to ensure the short-term and long-term effects of nanomedicines in humans. This review discusses the advantages of various drug delivery vehicles for better understanding of their utility in terms of current medical needs. Furthermore, the application of a wide range of nanomedicines is also described in the context of major chronic diseases.

Systemic Review of Biodegradable Nanomaterials in Nanomedicine

“…Several anti-inflammatory nanomedicines have been developed for targeted treatment of atherosclerosis, ischemia/reperfusion and post myocardial infarction left ventricular remodeling [32]. However, so far the targeted therapy in cardiovascular diseases using nanomaterial-based drug delivery vehicles have only shown effectiveness in preclinical settings [92]. Limitations lie in the gap in the knowledge of clinical safety, the requirement of composition purity and long-term stability of payload, as well as challenges and cost in scaled up production [93].…”

Nanocarriers as Magic Bullets in the Treatment of Leukemia

“…To be eligible for in vivo applications, nanosystems must be composed of materials that are biocompatible, non-toxic, and biodegradable [17]. Moreover, they should be stable after administration and, in view of possible clinical translation, their preparation as easily up-scaled for manufacturing with a high control over their physicochemical properties [14].…”

Injectable Hydrogel-Based Nanocomposites for Cardiovascular Diseases

“…At present, drug-encapsulated hydrogel treatment mainly focuses on finding suitable natural or chemical drugs that change the environment of tissue lesions, and designing suitable injectable hydrogel delivery systems. Moreover, the sustained-release effect of the DDS also affects the treatment of cardiovascular disease (Singh et al, 2019). It is worth noting that an injecting TIIA@PDA Nanoparticle-Cross-linked ROS-Sensitive Hydrogels as a nanoscale DDS roperly control of the drug release amount because TIIA@PDA NPs can be seized via the chemical bond between thiolate and quinone groups on PDA .…”